[144] SOPHiA GENETICS SA SEC Filing

Rhea-AI Filing Summary

SOPHiA GENETICS SA reporting a Form 144 notice: an insider proposes to sell 21,000 common shares through Morgan Stanley Smith Barney on 09/23/2025 on NASDAQ with an aggregate market value of $82,530.00. The shares were acquired 06/24/2024 in a Pre-IPO transaction from the issuer and were paid for on the acquisition date. Total shares outstanding reported are 67,579,560, so the proposed sale equals approximately 0.031% of outstanding shares. The filer certifies no undisclosed material adverse information and provides no other sales in the past three months.

Positive

• Complete Rule 144 fields provided including acquisition date, broker, proposed sale date, and aggregate value
• Transaction executed through a major broker (Morgan Stanley Smith Barney), suggesting standard orderly sale procedures
• Sizable time gap not required because shares were acquired in a Pre-IPO transaction and payment was completed on acquisition date

Negative

• Insider sale disclosed, which some investors may interpret unfavorably despite small size
• Form shows no recent sales in prior three months, but does not provide context on insider's broader holdings or intentions

Insights

Securities Analyst

TL;DR: Small, routine insider sale disclosed; insufficient size to be materially dilutive.

The filing shows a proposed sale of 21,000 shares valued at $82,530, representing roughly 0.03% of outstanding stock. From a market-impact perspective, this size is immaterial relative to the 67.6 million shares outstanding and is unlikely to move the stock price. The shares were acquired in a pre-IPO transaction and are being sold through a major broker on NASDAQ, indicating a standard liquidity event rather than a financing or deleterious transaction.

Compliance / Corporate Governance Expert

TL;DR: Disclosure appears complete for Rule 144 purposes; representation about material information is included.

The notice includes required fields: acquisition date, nature of acquisition (Pre-IPO), broker details, proposed sale date, aggregate market value, and outstanding shares. The signer affirms no undisclosed material adverse information and indicates no securities sold in the prior three months. This satisfies routine Rule 144 disclosure practices; any regulatory or governance concern would depend on corroborating public disclosures, which are not part of this form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	21000	82530.00	67579560	09/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/24/2024	Pre-IPO	Issuer			21000	06/24/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares is SOPH insider proposing to sell?

The notice reports a proposed sale of 21,000 common shares of SOPHiA GENETICS SA.

When is the proposed sale scheduled and on which exchange?

The proposed sale date is 09/23/2025 and the sale is to occur on NASDAQ through Morgan Stanley Smith Barney.

What was the acquisition date and nature of acquisition for the shares?

The shares were acquired on 06/24/2024 in a Pre-IPO transaction from the issuer, with payment completed on that date.

What is the aggregate market value and how large is the sale relative to outstanding shares?

Aggregate market value is reported as $82,530.00; the 21,000 shares represent approximately 0.031% of the 67,579,560 shares outstanding.

Has the filer sold any issuer securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.